

# ***Scurfy Mouse (outside)***




***Wild type***

***Scurfy***

- **X-linked recessive inheritance**
- **Lethality at 21-25 days**
- **Wasting syndrome**
- **Exfoliative dermatitis**
- **Small, thickened ears**

# ***Scurfy Mouse (inside)***




***Wild type***

***Scurfy***

- Severe autoimmune disorder
- Hepatosplenomegaly
- Enlarged lymph nodes
- Multi-organ lymphocytic infiltrates
- Elevated cytokines (GM-CSF, IL-2, -4, -5,-6,-7, -10, IFN- $\gamma$ , TNF $\alpha$ )





# CD4<sup>+</sup> T cells are hyper-active in Scurfy mice




# Scurfy T cells are insensitive to inhibitors

Cyclosporin A dose vs. IL2 response



- 
- I** Immune deficiency/dysregulation
  - P** Polyendocrinopathy
  - E** Enteropathy (Often have Ab against gut epithelium)
  - X** X-linked inheritance

# IPEX – Outside (Clinical Findings)



- First described in 1982 by Powell et al. as a syndrome of diarrhea, polyendocrinopathy, and fatal infection in infancy.
- Neonatal onset diabetes mellitus
- Hypothyroidism
- Enteritis (diarrhea/villous atrophy)
- Hemolytic anemia & thrombocytopenia.
- Dermatitis
- Dermatitis (eczema)
- Death by 1-2 years of age


# IPEX – Inside (Autopsy Findings)

- Pancreas: islets of Langerhans absent with lymphocytic infiltrates
- Intestine: villous atrophy with lymphocytic infiltrates
- Liver: Cholangitis
- Spleen: enlarged
- Lymph nodes: Follicular hyperplasia
- Thyroid: Lymphocytic infiltrates
- Lungs: Consolidation/Inflammation
- Thymus: Atrophy



# Mapping of the Scurfy genetic region


X Chromosome ~500 genes



# FOXP3 Encodes a Novel Forkhead/ Winged-Helix Protein

## Foxp3

MPNPRPAKPMAPSLALGPSGLPSWKTAPKGSELLGTRGPGGGPFQGRDLRSGAHTS  
SSLNPLPPSQLQLPTVPLVMVAPSGARLGPSPHLQALLQDRPHFMHQLSTVDAHAQT  
PVLQVRPLDNPAMISLPPPSAATGVFSLKARPGLPPGINVASLEWVSREPALLCTFP  
RSGTPRKDSNLLAAPQGSYPLLANGVCKWPGCEKVFEPEEFLKHCQADHLLDEK GK  
AQCLLQREVVQSLEQQLELEKEKLGAMQAHLAGKMALAKAPSVASMDKSSCCIVATS  
TQGSVLPAWSAPREAPDGGLFAVRRHLWGSHGNSTFPEFFHNMDYFKYHNMRPPFTY  
ATLIRWAILEAPERQRTLNEIYHWFTRMFAYFRNHPATWKNAIRHNLSLHKCFVRVE  
SEKGAVWTVDEFEFRKKRSQRPNKCSNPCP



# Mouse and human scurfy gene products are highly conserved (86% identity)

```

m Foxp3 MPNPRPAKFMAPSALALGSPSPGVLPSWKTAPKGSSELLGTRGSGGPFQGRDL 50
h FOXP3 MPNPRPGKPSAPSALALGSPSPGASPSWRAAPKASDLLGARGPGGTFQGRDL 50

m Foxp3 RSGAH.TSSSLNPLPSSQLQLPTVPLVMVAPSGARLGPSPHLQALLQDRP 99
h FOXP3 RGGAHASSSSLNPMPPSOLQLPTLPLVMVAPSGARLGPLPHLQALLQDRP 100

m Foxp3 HFMHQLSTVDAHAQTPVLQVRPLDNPAMISLPPPSAATGVFSLKARPGLP 149
h FOXP3 HFMHQLSTVDAHARTPVLVQVHPLESPAMISLTPPTTATGVFSLKARPGLP 150

m Foxp3 PGINVASLEWWSREPALLCTFPRSSTPRKDSNLLAAPQGSYPLLANGVCK 199
h FOXP3 PGINVASLEWWSREPALLCTFFNPSAPRKDSTLSAVPQSSYPLLANGVCK 200

m Foxp3 WPGCEKVFEPEEFLLKHCQADHLLDEKGAQCLLQREVMQSLQOLELEK 249
h FOXP3 WPGCEKVFEPEDEFLKHCQADHLLDEKGRAQCLLQREMVMQSLQQLVLEK 250

m Foxp3 EKLGAHQAHLAGKMALAKAPSVASMDKSSCCIVATSTOGSVLPAAWAPRE 299
h FOXP3 EKLSAMQAHLAGHMALTKASSVASSDKGCCIVAAGSQGPVVPAAWSPRE 300

m Foxp3 APDGGFLFATPHLWGSNHSFPEFFHNMDYFKYHNRPPPTYATLIRWA 349
h FOXP3 APD.SLFAVPHLWGSNHSFPEFLHNMDYFKFHNRPPPTYATLIRWA 349

m Foxp3 ILEAPERQRTLNEYHWFTRMFAYFRNHPATWKNAIRHNLSLHKCFVRVE 399
h FOXP3 ILEAPEKQRTLNEYHWFTRMFAFFRNHPATWKNAIRHNLSLHKCFVRVE 399

m Foxp3 SEKGAVWTVDEFERKRSQRPNKCSNPPCP.. 429
h FOXP3 SEKGAVWTVDELEFRKRSQRPSRCSNPTTGP 431

```



# What does FOXP3 do?

## 1 – Rheostat of the immune response

*Khattri R, et al., J. Immunol. 2001*

## 2 – Plays an essential role in the development and function of CD4<sup>+</sup>CD25<sup>+</sup> Regulatory T cells

*Hori S, et al., Science 2003*

*Khattri R, et al., Nat. Immunol. 2003*

*Fontenot JD, et al., J. Nat. Immunol. 2003*

## 3 – FOXP3 may function as a transcriptional repressor of cytokine promoters


*Schubert L, et al., J. Biol. Chem. 2001*




# ***5 Habits of Highly Effective Transcription Factors***

- 1. Nuclear import – may be regulated**
- 2. Interaction with partners (homo- or heterodimerization)**
- 3. DNA binding**
- 4. Transcriptional enhancement or suppression at specific gene promoters**
- 5. Down regulation (nuclear export / degradation)**

# FOXP3 is a rheostat of the immune response





# What is known about FOXP3 mediated gene transcription

**1 -- FOXP3 may function as a transcriptional repressor of cytokine promoters**

*Schubert L, et al., J. Biol. Chem. 2001*

**2 – PBMC from patients with IPEX show poor up-regulation of IFN- $\gamma$  production in response to activation**

*Chatilla TA, et al., JCI 2000*

*Neives D, et al., Arch. Dermatol. 2003*

# CD4<sup>+</sup>CD25<sup>+</sup> Regulatory T Cells


- Make up 5-10% of the normal CD4<sup>+</sup> T cell population
- Characterized by expression of CD4 and CD25 on the cell surface at baseline. Cytotoxic T-Lymphocyte associated Antigen-4 (CTLA-4), Glucocorticoid-Induced Tumor-necrosis factor receptor-Related protein (GITR), Transforming Growth Factor  $\beta$  (TGF $\beta$ ), and Interleukin-10 (IL-10) have all been reported to play a role in T<sub>reg</sub> function but are not specific to T<sub>reg</sub> cells
- Require activation and cell contact to repress proliferation of other T cells but do not appear to proliferate themselves after activation.





# Goals

- **To better define the clinical phenotype of IPEX**
- **To understand the molecular structure and function of FOXP3:**
  - **What does it do – transcriptional regulation?**
  - **How is it regulated?**
  - **What does it regulate?**
- **To use the Scurfy mouse and naturally occurring human mutations as models to study the development and function of Regulatory T cells**

# FOXP3 Mutations



# FOXP3 Mutations in IPEX



	<u>Nucleotide</u>	<u>Amino Acid</u>	<u>Ref</u>		<u>Nucleotide</u>	<u>Amino Acid</u>	<u>Ref</u>
1.	112G>T <sup>a</sup>	A38S		A.	747_749delAAG	K250del	21
2.	210G>T <sup>a</sup>	Q70H		B.	IVS9+459A>G		5
3.	227delT	L76fsX128	8	C.	1040G>A	R347H	21
4.	303_304delTT <sup>a</sup>	F102fsX101		D.	1087A>G	I363V	8
5.	543C>T	Splicing	20	E.	1113T>G	F371L <sup>b</sup>	7
6.	750_752delIGGA	E251del	5	F.	1290_1309del/insTGG	G430fsX452 <sup>b</sup>	7
7.	776A>C <sup>a</sup>	H259P					
8.	1010G>A <sup>a</sup>	R337P					
9.	1099T>C <sup>a</sup>	F367L					
10.	1150G>A	A384T	6,7				
11.	1189C>T	R397W	7				
12.	1190G>T <sup>a</sup>	R397L					
13.	1271G>A <sup>a</sup>	C424Y					
14.	1293_1294delICT	P431fsX457	6				
15.	AAUAAA>AAUGAA	Polyadenylation	16				

<sup>a</sup> Newly identified mutation



<sup>b</sup> The indicated amino acid change differs from that originally reported but is the sequence that results from the reported nucleotide change.

# Human *FOXP3* Promotor Structure



- Is there a tissue-specific repressor that limits *FOXP3* expression to the CD4<sup>+</sup>CD25<sup>+</sup> population (similar to the CD4 or Btk promoters) or are there tissue-specific enhancers that lead to expression only in this cell type?

# Human *FOXP3* Promoter Structure



# *Summary*

1. We have identified 16 different mutations in patients with IPEX syndrome.
  - Patients with FOXP3 mutations have a more severe phenotype than those without mutations.
  - We have identified domains of the FOXP3 protein important for its function.
  - We have identified a deletion in the FOXP3 promoter that leads to low FOXP3 mRNA expression levels.

# A Better Picture of IPEX

25 kindreds (31 patients) with the IPEX phenotype:

Clinical data obtained from 24 kindreds by questionnaire to PMD:

-*FOXP3* mutations found in 14 kindreds (17 patients) – “IPEX”

-No *FOXP3* mutation in 10 kindreds (10 patients) – “IPEX-like”

IPEX: 100% have enteropathy diarrhea, often bloody

100% have skin disease – eczema (most), erythroderma

80-90% have one endocrinopathy – usually IDDM or thyroid

60% have glomerulonephropathy – often mild

50% have autoimmune hematologic problems: hemolytic anemia, thrombocytopenia, or neutropenia.

90+% have failure to thrive and ~40% have developmental delay or neurologic abnormality (seizures, etc).

50-60% have one or more major infections (sepsis, osteo, etc.)

Treatment Options: CsA, FK506, Steroids, BMT

# Skin Disease in IPEX





# The Expanding IPEX Phenotype

## *Kindred I-9:*

- The original IPEX kindred. A large family with several affected males, some who lived into adulthood.
- Mutation in the first Polyadenylation site – leads to decreased mRNA levels. Variations in mRNA processing may account for variable phenotype.
- Immune activation (severe illness/vaccinations) caused rapid worsening of disease in some patients.




## ***Kindred I-11:***


- 12 year old male with Diarrhea starting at 6 m/o, bloody stools ~ 1 year ago – Dx'd with Crohn's disease by biopsy
- Autoimmune Hyperthyroidism diagnosed at 5 y/o and ablated with I<sup>125</sup> therapy
- Severe eczema over last 2 years with numerous superinfections
- Neutropenia over last 1-2 years with anti-neutrophil antibodies
- Elevated IgE (1080 gm/dl)
- Mutation in the first base of Exon 5 (Splicing?)

# Quantitative RT-PCR of *FOXP3* Expression in IPEX-like Patients

A



B



# ***Scurfy Mouse - Immunology***

- Mediated by CD4<sup>+</sup> T cells – adoptive transfer
- Overproduction of cytokines IL-2, 4,5,6,10;  
IFN $\gamma$ , TNF $\alpha$ , GM-CSF
- $\uparrow$  Mac-1<sup>+</sup>,  $\downarrow$  B220<sup>+</sup>
- $\uparrow$  Activation antigens CD69, CD25, CD80, CD86
- Scurfy T cells  $\downarrow$  sensitivity to tyrosine kinase Inhibitors (genistein, herbimycinA) and to cyclosporin A

# ***Scurfy Mouse - Immunology***

- Mediated by CD4<sup>+</sup> T cells – adoptive transfer
- Overproduction of cytokines IL-2, 4,5,6,10;  
IFN $\gamma$ , TNF $\alpha$ , GM-CSF
- $\uparrow$  Mac-1<sup>+</sup>,  $\downarrow$  B220<sup>+</sup>
- $\uparrow$  Activation antigens CD69, CD25, CD80, CD86
- Scurfy T cells  $\downarrow$  sensitivity to tyrosine kinase Inhibitors (genistein, herbimycinA) and to cyclosporin A

# *Expression of Foxp3*

- Spleen strong
- Thymus strong
- CD4+ CD8- strong
- Cd4- cd8+ >
- B220 > Barely detectable



# ***All Forkhead/HNF3 Proteins Possess “Winged-Helix” Domain***

- ~110 amino acid domain
- Involved in DNA binding
- Forkhead/hnf3 proteins act as **transcriptional regulators**
  - (Examples of activators and repressors)
- Large gene family:
  - Found in all species; Involved in many different processes (eg., Development, organogenesis, tumorigenesis)

# **Scurfy gene/mutation**

- Proximal X-chromosome
- Tightly linked (but not synonymous) to Wasp
- Novel forkhead gene
- 2 base pair deletion, frameshift
- Exon 8 (proximal to forkhead domain)
- Early termination – truncated protein
- Loss of function



# Scurfin

(transcriptional regulator)

- 47 KD protein
- 429 a.a. (mouse)
- 431 a.a. (human)
- 3  $\alpha$  helices
- 2 loop regions (“wings”)
- Zinkfinger domain
- Forkhead domain (116 a.a. downstream of ZF mediates protein – DNA contact)



# Scurfin - mutated

- Failure to control T cell function
- Mutations of : Scurfin
  - CD95, CD95
  - ligand
  - CTLA-4
  - TGF- $\beta$
- Scurfy mouse resembles
  - Knockout of CTLA-4 and TGF- $\beta$

Syndrome	WAS	XLT/IXLT	XNP	XLT/ thalassemia trait	IPEX
gene	WASP prot. –	WASP prot.+	WASP L270P	GATA-1	FOXP3
Thrombo- cytopenia	yes	yes / (yes)	no	yes	yes
anemia	(yes)	(yes)	no	yes (Hgb synthesis)	yes
neutropeni a	no	no	yes	no	(yes)
endocrine	no	no	no	no	yes
GI- problems	(yes)	no	no	no	yes



# **FOXP3 - function (1)**

- Forkhead (FKH) proteins regulate lineage commitment, developmental differentiation
- Scurfin localizes to the nucleus  
FKH domain required
- FKH binding sites adjacent to NFAT sites were identified in cytokine Promoters

## **FOXP3 - function (2)**

- **FOXP3 transgenic mice overexpress scurfin**  
decrease of Tcell number (ly nodes, spleen)  
poor proliferation  
decreased IL-2. IFN gamma  
decreased expression of CD40L  
reduced Ab responses to T dependent Ag



# APECED

- Autoimmune
- Polyendocrinopathy
  - Candidiasis
- Ectodermal Dysplasia



# **APECED - Clinical phenotype**

- **Chronic mucocutaneous candidiasis**
- **Hypoparathyroidism**
- **Addison Disease**
- **Diabetes, type 1, gonadal atrophy, pernicious anemia, hypothyroidism**
- **Autoimmune hepatitis**
- **Ectodermal dysplasia: enamel, nails, alopecia, vitiligo, calcification of TM**

# APECED -Founder Effect

	Finnish	Sardinia	Iran Jews	N-America
Incidence	1:25K	1:14K	1:9K	16
N	67	11	16	75
MCC	100%	83	18	100
Hypopara	79%	93	96	93
Adrenal	72%	73	22	not rep.
Nails	52%	not rep.	most	C322
Predomin. AIRE	R257X	R139X	Y85C	de113
mutation	Exon 6	Exon 3	Exon 2	bp>stop





# **APECED - genetics (1)**

- Mapped to 21 822.3
- Gene: Autolimmune REgulator (AIRE)
- Function: transcriptional regulator, has characteristic domains for Induction and maintenance of immune function
- 14 exons, encoding a 545 aa protein
- Expressed in Thymus epithelium, lymphnodes, spleen, fetal liver



## **APECED genetics (3)**

- 45 known mutations of AIRE
- Distributed throughout the AIRE gene
- Variable clinical phenotype
  - type of mutation
  - environmental
  - HLA-DR (B 103 - Addison disease)
  - (B 104 - alopecia)

# **APECED Aire-knockout mice**

- **APECED features**
- **Lymphocytic infiltrates (ovary, liver)**
- **Atrophy of thymus, adrenals, ovaries (42%)**
- **Autoimmune hepatitis (50%)**
- **Autoantibodies (73%), testes (8/15), liver (3/15), pancreas (7/15), adrenal gland (3/15)**
- **In vitro hyperproliferation of sensitized Ly**

## ALPS - genetics

- Autosomal dominant (mostly), or recessive
- Mutations of *APO-1* encoding Fas/APO-1/CD95 is present in most ALPS
- Mutation of FasL or Caspase 10 is rare
- Animal models: *lpr* mutation (Fas)  
*gld* mutation (FasL)  
phenotype is strain dependent

**IPEX  
(FOXP3)**

malabsorption

Alopecia  
Endocrino-  
pathies

Immune  
dysregulation  
Diarrhea  
Skin  
rashes

**Auto  
antibody  
Lymphocytic  
infiltrates  
Tx: immuno-  
suppressive**

T cell defect  
Hepatitis  
Ectodermal  
dysplasia

Apoptosis  
Double negative  
 $\alpha\beta$  T cells  
lymphoma

Hyper  
IgG, M, A

**ALPS  
(Fas/FasL/  
Caspase10)**

**APECED  
(Aire)**

